OR
Showing 1 - 25 of >10,000
Gastric Cancer, Gastroesophageal-junction Cancer, Advanced Cancer Trial (TST001, CapOx or mFOLFOX6 and NIVO or (Substudy)
Not yet recruiting
- Gastric Cancer
- +2 more
- TST001, CapOx or mFOLFOX6 and NIVO or (Substudy) TST001, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)
- Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)
- (no location specified)
Oct 16, 2023
Surgical Site Infection Trial (Novosyn® in emergency or elective laparotomy or laparoscopic surgery, Polyglactin 910 in
Not yet recruiting
- Surgical Site Infection
- Novosyn® in emergency or elective laparotomy or laparoscopic surgery
- Polyglactin 910 in emergency or elective laparotomy or laparoscopic surgery
- (no location specified)
Jul 28, 2023
Prospective, Multi-Center, Observational, Whole Blood Specimen
Not yet recruiting
- Rheumatoid Arthritis
- (no location specified)
Jun 30, 2023
Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation Trial (Onvansertib, FOLFIRI, Bevacizumab)
Not yet recruiting
- Metastatic Colorectal Cancer
- +2 more
- Onvansertib
- +3 more
- (no location specified)
Oct 24, 2023
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1
Not yet recruiting
- Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
- Ivosidenib 500mg
- Placebo
- (no location specified)
Nov 7, 2023
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma Trial (Cadonilimab, AK117, Oxaliplatin)
Not yet recruiting
- Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
- Cadonilimab
- +5 more
- (no location specified)
Jul 17, 2023
HER2-PositiveRecurrent or Metastatic Breast Cancer Trial (SHR-A1811 Injection, SHR-A1811 Injection ; Pertuzumab Injection,
Not yet recruiting
- HER2-PositiveRecurrent or Metastatic Breast Cancer
- SHR-A1811 Injection
- +2 more
- (no location specified)
Sep 21, 2023
NSCLC (NSCLC) Trial (MK-2870, Docetaxel, Pemetrexed)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- MK-2870
- +2 more
- (no location specified)
Oct 3, 2023
Obesity Trial (BI 456906, Placebo)
Not yet recruiting
- Obesity
- BI 456906
- Placebo
- (no location specified)
Oct 4, 2023
Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)
Recruiting
- Relapsed or Refractory Hodgkin Lymphoma
- SHR2554+ SHR1701
- SHR-1701
-
Beijing, Beijing, ChinaHan wei dong
Jun 14, 2023
Metastatic Colorectal Cancer Trial in Houston (Cetuximab, Ulixertinib, Encorafenib)
Not yet recruiting
- Metastatic Colorectal Cancer
- Cetuximab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2023
Metastatic Castration-resistant Prostate Cancer Trial (Darolutamide, Docetaxel or cabazitaxel)
Not yet recruiting
- Metastatic Castration-resistant Prostate Cancer
- Darolutamide
- Docetaxel or cabazitaxel
- (no location specified)
Feb 28, 2023
Lupus Erythematosus, Cutaneous, Subacute, Chronic Cutaneous Lupus Erythematosus Trial (BIIB059 (litifilimab))
Not yet recruiting
- Lupus Erythematosus, Cutaneous, Subacute
- Chronic Cutaneous Lupus Erythematosus
- BIIB059 (litifilimab)
- (no location specified)
Sep 12, 2023
Pre-Eclampsia, Obesity Trial in Le Mans (Hypocaloric diet, Dissociated diet)
Recruiting
- Pre-Eclampsia
- Obesity
- Hypocaloric diet
- Dissociated diet
-
Le Mans, FranceCentre Hospitalier Du Mans
Sep 28, 2023
Alopecia Areata Trial in Randwick (OR-101 (Single ascending dose), OR-101 (Food effect), OR-101 (Multiple ascending dose))
Not yet recruiting
- Alopecia Areata
- OR-101 (Single ascending dose)
- +3 more
-
Randwick, New South Wales, AustraliaSCIENTIA Clinical Research Ltd
Sep 13, 2023
Lymphoma, Mantle-Cell Trial in Shanghai (Zanubrutinib, Rituximab, Bendamustin)
Not yet recruiting
- Lymphoma, Mantle-Cell
- Zanubrutinib
- +2 more
-
Shanghai, Shanghai, ChinaRuijin Hospital
Nov 14, 2023
Joint Prosthesis; Complications Trial in Paris (joint puncture)
Recruiting
- Joint Prosthesis; Complications
- joint puncture
-
Paris, FranceGroupe Hospitalier Diaconesses Croix saint Simon
Sep 19, 2023
Overweight or Obesity Trial in Chicago (Sleep Extension, Sleep Regularity)
Not yet recruiting
- Overweight or Obesity
- Sleep Extension
- Sleep Regularity
-
Chicago, IllinoisUniversity of Chicago
Nov 7, 2023
Lung Cancer, NSCLC, Brain Metastases Trial (Alectinib, Stereotactic Radiosurgery)
Not yet recruiting
- Lung Cancer
- +2 more
- Alectinib
- Stereotactic Radiosurgery
- (no location specified)
Aug 4, 2023
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811, Ramucirumab / Paclitaxel/
Not yet recruiting
- HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
- SHR-A1811
- Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
- (no location specified)
Nov 6, 2023
Cadonilimab in Recurrent or Metastatic Cervical Cancer
Not yet recruiting
- Recurrent or Metastatic Cervical Cancer
- (no location specified)
Nov 23, 2023
Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma Trial in Shanghai (Phase I
Not yet recruiting
- Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma
- Phase I dose escalation
- +3 more
-
Shanghai, Shanghai, ChinaFudan Cancer Hospital
Apr 24, 2023
Acute Myeloid Leukemia, MDS Trial in United States (GLB-001)
Recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
-
Duarte, California
- +3 more
Nov 21, 2023
Cerebral Aneurysm Trial in Roma (Endovascular embolization or surgery)
Recruiting
- Cerebral Aneurysm
- Endovascular embolization or surgery
-
Roma, RM, ItalyFondazione Policlinico Universitario A.Gemelli IRCCS
Feb 6, 2023